NCT03583528 2025-06-13DOTATOC PET/CT for Imaging NET PatientsBritish Columbia Cancer AgencyActive not recruiting800 enrolled
NCT00427349 2023-07-05AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsEastern Cooperative Oncology GroupPhase 2 Completed46 enrolled 7 charts
NCT00227617 2023-05-22Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsUniversity of California, San FranciscoPhase 2/3 Terminated36 enrolled 14 charts
NCT04915144 2023-02-21177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsBritish Columbia Cancer AgencyPhase 2 Withdrawn
NCT00050349 2017-03-01EPO906 in Carcinoid and Other Neuroendocrine TumorsNovartisPhase 2 Completed33 enrolled
NCT00869050 2016-07-25Capecitabine and Temozolomide for Neuroendocrine CancersColumbia UniversityPhase 2 Completed41 enrolled 9 charts